R&D Strategies for creating an ecosystem to support early-stage ... Learn how to foster growth for early-stage biotech companies through innovative ecosystem strategies and valuable CDMO collaborations
Market Access How can biotech survive its funding winter? Some may argue that VCs and public markets have turned against biotech, but the reality is they have become much more sceptical.
Market Access From roasts to billions: Navigating the biopharma investment... At BIO-Europe, the session “From Roasts to Billions: Biopharma Investment Landscape” brought together leading voices from investment banking & VC.
R&D The glimmer of opportunity behind the storm: Ali Pashazadeh ... Former surgeon and investment banker Ali Pashazadeh, CEO of Treehill, discusses the current ‘perfect storm’ in biotech.
Market Access Biotech ≠ tech: Why venture capital needs a new playbook for... Silicon Valley investors have been conditioned by two decades of software: launch quickly, capture users faster, and hit the magic $1 million ARR mark within about three years,1
Market Access BIO Boston: 2025 is shaping up to be a year of challenge – b... What were the major themes to come out of BIO Boston 2025? Despite global events in the background, a fair amount of positivity.
News NHS "isn't delivering equitable care for rare diseases" A Genetic Alliance UK report claims the NHS is failing to meet the needs of many of the 3.5 million people in the country who live with rare diseases.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.